Yuval Cohen, Ph.D., joined Corbus as co-founder and Chief Executive Officer in 2014. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq: CLTX) from 2005 to June 2013. Dr. Cohen has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V.

Rachael Brake, Ph.D., has successfully developed innovative drug discovery and clinical development oncology programs centered around patient-focused, unmet medical needs. Prior to joining Corbus in 2021, Dr. Brake most recently served at Takeda Pharmaceuticals where she held multiple leadership roles across the R&D continuum, including serving as Vice President, Global Project Leader in Oncology. In this position, she managed a portfolio of programs and cross-functional teams responsible for the preclinical and clinical exploration of various solid tumor drug candidates spanning diverse mechanisms of action. She is experienced in early- and late-stage clinical development, regulatory approvals (ALUNBRIG®, EXKIVITY™), program externalizations (DAY101, sapanisertib), and commercialization efforts. In her most recent role as the Head, U.S. Medical Affairs, in the Oncology Business Unit, Dr. Brake developed a medical strategy for Takeda Oncology’s portfolio and emerging immune-focused pipeline. Prior to her tenure at Takeda, Dr. Brake held leadership roles in Research at Amgen Inc. and Millennium Pharmaceuticals, Inc. Dr. Brake obtained her Ph.D. in Molecular Biology and Biochemistry from the University of Western Australia Perth. She also received a Bachelor of Science from the Australian National University.

Sean Moran, CPA, joined Corbus in January 2014. He has more than twenty years of senior financial experience with emerging biotechnology, drug delivery, and medical device companies. Mr. Moran has successfully managed operations from start up through development to commercialization and profitability. He has completed three IPOs and has raised more than $500 million of capital. Before joining Corbus, Mr. Moran served as Chief Financial Officer for InVivo Therapeutics, Celsion Corporation, Echo Therapeutics, and Anika Therapeutics. Mr. Moran earned his M.B.A. and a B.S. in Accounting from Babson College in Wellesley, MA.

Christina Bertsch joined Corbus in April 2020. She is an accomplished senior human resource executive providing strategic HR consulting services to both large and small businesses across a variety of industries. Her expertise spans the full employee lifecycle including talent acquisition, workforce development, performance management, succession planning, total rewards as well as employee engagement and retention. In addition to her expertise, Christina also has significant experience in HR strategic planning, mergers & acquisitions, change management, executive coaching & development and building scalable HR infrastructures for growing companies.

Ms. Bertsch has worked with a number of organizations within the life sciences space including Stoke Therapeutics, Jounce Therapeutics, Magenta Therapeutics, Ironwood, Bruker, Merus, and Sarepta Therapeutics. Previous to starting her consulting business she was Senior Vice President of Human Resources at Santander Holdings US, Vice President of Human Resources at Beacon Partners and Director of Talent Management & Development at EMD Serono.

She holds a Bachelor’s Degree from Manhattanville College, and a Master’s Degree in Industrial / Organizational Psychology from Hofstra University.